EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Amivantamab-vmjw

EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Amivantamab-vmjw

Should clinicians be aware of any drug interactions? [...]there are no drug interactions to watch for with this product. Overall, the approval of amivantamab is a positive development for patients with lung cancer, and it adds another targeted option for those patients with limited therapy options a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology (Williston Park, N.Y.) N.Y.), 2022-03, Vol.36 (3), p.186
1. Verfasser: Bryson, Evan B
Format: Artikel
Sprache:eng
Schlagworte:
Cancer therapies
Care and treatment
Chemotherapy
Drug dosages
Drug interactions
Edema
FDA approval
Lung cancer
Lung cancer, Non-small cell
Metastasis
Monoclonal antibodies
Mutation
Oncology
Patients
Targeted cancer therapy
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Should clinicians be aware of any drug interactions? [...]there are no drug interactions to watch for with this product. Overall, the approval of amivantamab is a positive development for patients with lung cancer, and it adds another targeted option for those patients with limited therapy options after progression on platinum-based chemotherapy. Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study.
ISSN:0890-9091